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INTRODUCTION

C
rohn's disease (CD) is a chronic infl ammatory disorder which may involve every part of the gastrointestinal tract. The illness often passes asymptomatically and may take up to several years to be diagnosed [1] . CD may have some severe complications which negatively impact the quality of life and could lead to necessity of surgical treatment [2] . The complications in patients with CD are two major types -intestinal and extraintestinal [3] . The most common intestinal complications are an obstruction, formation of a fi stula, perforation, abscesses forming a collection of pus, and intestinal bleeding [4] . Patients are obliged to the chronic infl ammation that produces scar tissue known as stricture and deep ulcers, which are very peculiar for CD [1] . It is thought that immune and genetic factors (as HLA genes) are involved in the pathogenesis of extraintestinal manifestations.
Extraintestinal features in CD patients are presented as eye complications, arthropathy, skin and oral lesions, delayed growth in children, etc. Some of these complications may have an association with disease activity, like episcleritis, but others, i.e., pyoderma gangrenosum, may not correlate with disease activity [3] . However, in general, extraintestinal manifestations tend to follow the clinical course of CD and may have huge impact on the quality of life, morbidity and even mortality [3, 5, 6] . The complications that are associated with the activity of CD could respond to treatment of the bowel disease, but there is no specifi c treatment available for them [5] . Some conditions are associated with the damaged function of the intestine, like gallstones and kidney stones, anemia, osteomalacia, sensory disturbances (zinc defi ciency, vitamin B defi ciency) [1] . The delicate mechanism is related to the impaired absorption and malnutrition or the side effects of therapy ( Figure 1 ) [7] . Both intestinal and extraintestinal complications contribute to increased morbidity and mortality of patients with CD. Thus, they are of growing health burden for these patients. This is the reason why it is crucial these complications and manifestations to be uncovered in time. The complications can occur, particularly during frequent or severe fl are-ups [1] . Since there are some validated laboratory and immunologi-cal fi ndings (i.e., CRP, ESR, fecal calprotectin, etc.) that may be used to assess the disease activity, we aimed to search for some associations between specifi c extraintestinal manifestation and intestinal complications in CD patients with some clinico-laboratory fi ndings and immunological markers. We also questioned whether the therapy administered infl uences the occurrence of complications.
MATERIALS AND METHODS
Patients
We examined retrospectively medical fi les of 26 patients with CD, diagnosed and treated in the Clinic of Gastroenterology at University Hospital "Sv. Ivan Rilski" from 2011 to 2012. The diagnosis was confi rmed by colonoscopy plus biopsy and MRI.
All patients have signed the informed agreement, and the study was approved by the Ethic Committee of the Medical University of Sofi a.
Eight men (30.8%) and 18 women (69.2%) at mean age 42 ± 13 years (range 21-71 years) were examined. The activity of the disease was assessed by CDAI (Crohn's disease activity index). The overwhelming proportion of the patients was at a state of activity (77.9%). We divided patients into groups according to treatment regimens, Montreal classifi ed localisation of the disease [8] , and disease duration ( Table 1) .
We collected clinical and laboratory data from medical fi les of the patients retrospectively. We found the following registered extraintestinal manifestations in patients: arthralgia/arthritis (n = 2), pyoderma gangrenosum (n = 1), and intestinal complications: fi stulas (n = 6), obstructions (n = 2), anal fi ssures (n = 4). We also used the laboratory fi ndings of the medical fi les for Creactive protein, iron, and hemoglobin in serum.
Immunological methods
The immunological markers fecal calprotectin (FC) and fecal lactoferrin (FL) were assessed in frozen (-80°C) fecal samples of the patients by performing qualitative card-tests (One step card test, Certest, Spain) at the Laboratory of Clinical Immunology, University Hospital "Sv. Ivan Rilski", Sofi a, according to manufacturer's instructions. The methods were based on lateral immunochromatographic diffusion, and the cut-off for both tests was 50 mg/kg.
Statistical methods
We performed descriptive statistics, T-test, correlation and other analytical techniques to achieve the aim of the study by using SPSS v.19 (IBM). We accept the results as signifi cant if p < 0.05.
RESULTS
Overall, 19 (73%) of the investigated CD patients had some extraintestinal manifestation and/or intestinal complications. We observed extraintestinal manifestations in 3/26 patients, 13/26 were with intestinal complications, and 3/26 had both (Table 2) .
Extraintestinal manifestations were documented more often in women with long-lasting and active disease (without reaching signifi cance, p > 0.05). All three patients with extraintestinal manifestations were positive for FC and 2/3 were positive for FL (Table 2) .
Intestinal complications occurred more often in patients with the active and long-lasting disease, however, non-signifi cantly (p > 0.05), also in women, in non-immunosuppressive treated patients, in patients with positive FC and FL (p > 0.05) ( Table 2 ). The intestinal complications were more frequent in women than men -55.6% vs. 37.5% respectively, regardless the state of activity (66.7% of patients were at a state of remission, and 45.0% of patients were at a state of activity when they had complications). However, 37.5% of men had none complications during the disease.
The overwhelming proportion of patients (66.7%) with long-lasting disease (up to 10 years) had at least one extraintestinal manifestation and/or intestinal complication, the most of these patients receiving non-immunosuppressive therapy, too.
The majority of the CD patients with positive FC and FL had intestinal complications. Positive markers were associated with the active state of the disease (according to CDAI).
We also found differences in some laboratory markers depending on the presence of complications. We observed higher serum level of CRP (24.49 mg/l vs. 3.13 mg/l, p = 0.010), slightly lowered serum level of hemoglobin (120 g/l vs. 145 g/l, p = 0.044) and about 2-fold lower iron level (7.23 μmol/l vs. 14.0 μmol/l, p = 0.019) in patients with intestinal complications compared to patients without complications, respectively (Figure 2 A, B, C) .
From the three patients with extraintestinal manifestations of the disease, one was on nonimmunosuppressive therapy and two -on immunosuppressive drugs. Four out of thirteen patients with intestinal complications were without immunosuppressive treatment at the time of our study, and nine out of thirteen -on immunosuppressive medications. Three patients with both intestinal and extraintestinal symptoms were divided in the three therapeutic groups, one in every group (non-immunosuppressive, immunosuppressive and immunosuppressive + biologic therapy) ( Table 2 ).
DISCUSSION
We found that patients with long-lasting (over ten years) disease have at least one intestinal complication/extraintestinal manifestation of CD (73% of the study group). This is not surprising since CD is a chronic progressive disease that begins as an infl ammation in the mucosa and then progressively develops over time to a more complex illness with stricture and fi stula formation [9] . Furthermore, it is found that half of the patients with a lasting disease over 20 years suffered from intestinal complications and half of the hospitalized patients needed surgical treatment within ten years from diagnosis [9, 10] . There are accumulated data that over 60% of CD patients develop structuring and penetrating complications, where twenty-year actual rates of infl ammatory, structuring and penetrating disease were 12%, 18% and 70%, respectively [11] . In our study 13/26 (50%) CD patients had intestinal complications which result is in line with the cited resources.
It is determined that disease phenotype is changed markedly over time, with nearly 80% of infl ammatory disease ultimately evolving into structuring or penetrating pattern of behavior. [12] . Moreover, it is shown that CD with early onset has more severe behavior and more extensive localization than the disease with a later start. It was mentioned above that the extraintestinal complications might be due to side effects of therapy or the damaged function of the intestines [12] . We found that our patients on immunosuppressive therapy had more intestinal complications than extraintestinal ones. The reason for that may lie in the fact that immunosuppressive drugs are necessary when the disease is severe which includes the presence of complications. Moreover, it is shown that early administration of immunosuppressants was associated with a decreased risk of surgical intervention for structuring and penetrating disease among CD patients [13] [14] [15] [16] . A. B.
C. It is thought that some extraintestinal complications arise simultaneously during the fl are of the bowel disease, and consequently, they can be infl uenced by the treatment of the fl are.
The next aspect of our study was to investigate the association between complications and the levels of some common laboratory fi ndings in CD patients. CRP is documented to be increased during the active stage of the disease and may achieve up to and above 200 mg/l depending on the disease severity and the individual capacity of producing acute phase proteins. Furthermore, 86% of CD patients with elevated CRP exhibited infl ammation at colonoscopy [18] . In our study, patients with intestinal complications showed about an 8-fold increase in CRP compared to patients without intestinal complications (p = 0.010). We also found alterations in hemoglobin (p = 0.044) and iron levels (p = 0.019) according to the presence of the complications. These tests are laboratory routine for CD patients, including pediatric patients. Other common laboratory abnormalities in CD patients also enlist anemia, thrombocytosis (> 450 x 109 cells per L), and elevated ESR (> 20 mm/per hour). At least one abnormal result was found for 72% of patients with IBD, and more than one in about 49% of them [19] .
We also found an association between high levels of fecal markers, FC and FL, and the frequency of complications in our group of CD patients. These outcomes are in confi rmation of our previously published results [20] . Fecal markers are well accepted for diagnosis, prediction of activity and response to therapy. The sensitivity and specifi city in identifying the activity of IBD by colonoscopy are shown to be 70-100% and 44-100%, respectively [18, 21] . In our study, we pointed out another utility of FC and FL, namely in identifying these patients with positive tests that may also have intestinal complications.
CONCLUSION
In our study, we obtained data in order to assess the associations between particular extraintestinal manifestation and intestinal complications in CD patients with some clinical and laboratory fi ndings (CRP, hemoglobin, serum iron), immunological markers (fecal markers -FC and FL), and the administered therapy. These results could be benefi cial for gastroenterologists in identifying patients at high risk for the development of complications and in the decision making for more aggressive therapy early after diagnosis.
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